Search
Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. … Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks.
Casein
go.drugbank.com/drugs/DB10516ApprovedCasein allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household setting, Non-Standardized Food Allergenic ExtractPlasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigationalThe composition of PPFh should be 5% of protein from which 83% should consist of albumin and no more of 17% should be globulin. … The plasma protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and globulin derived from human plasma.
Products: OCTAPLAS Blood Group OTaletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting … [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable
Methyprylon
go.drugbank.com/drugs/DB01107ApprovedIllicitWithdrawnMethyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events. … Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia.
Sacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalIt was approved by the FDA after being given the status of priority review for on July 7, 2015. … Inhibition of neprilysin therefore leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. … Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America.
Categories: Compounds used in a research, industrial, or household settingProducts: Nu-warfarinDanaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnWhile it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans [A32565].
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalHowever, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008. … It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome